Sitagliptin is a DPP-4 inhibitor that increases endogenous incretins (GLP-1 and GIP), stimulating glucose-dependent insulin secretion.
Also known as: Januvia
Inhibits DPP-4, increasing GLP-1 and GIP levels. Stimulates glucose-dependent insulin secretion and suppresses glucagon secretion.
Blocks DPP-4, preventing degradation of incretins GLP-1 and GIP. Elevated incretin levels stimulate insulin secretion only when glucose is elevated.
Oral bioavailability: 87%. Food does not affect absorption. Tmax: 1-4 hours.
Minimally metabolised (~16% via CYP3A4 with CYP2C8 contribution). ~79% excreted unchanged in urine. Low interaction potential.
~12.4 hours. Elimination: ~79% urine (unchanged), ~14% faeces.
No documented drug–drug interactions for this medicine.
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
